JP Patent

JP7169412B2 — 抗癌活性及び抗増殖活性を呈する２－アミノピリミジン－６－オン及び類似体

Assigned to デシフェラ ファーマシューティカルズ，エルエルシー · Expires 2022-11-10 · 4y expired

What this patent protects

Patent listed against Romvimza.

Drugs covered by this patent

Patent Metadata

Patent number
JP7169412B2
Jurisdiction
JP
Classification
—
Expires
2022-11-10
Drug substance claim
No
Drug product claim
No
Assignee
デシフェラ ファーマシューティカルズ，エルエルシー
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.